A study involving the fusion of recombinant neuraminidase to HER2-specific antibody trastuzumab was found to selectively desialylate of the tumor cell glycocalyx and increase the cell susceptibility to Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) and hence serve as a treatment for those cancer patients having lower levels of HER2 or resistance to trastuzumab [149]. This evidence concerns the gene ERBB2 and cancer.